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Abstract
OBJCTIVE: To compare the clinical efficacy of Tradi-
tional Chinese Medicine (TCM) to Western Medi-
cine in the treatment of primary Sjögren's syn-
drome (pSS).
METHODS:We collected randomized controlled tri-
als of TCM vsWestern Medicine for the treatment of
pSS in Chinese and foreign databases. The study
quality was evaluated as suggested in the Co-
chrane Handbook. The Meta-analysis was per-
formed using Review Manager 5.0 statistical soft-
ware.
RESULTS: A total of 31 randomized controlled trials
with 2137 cases were retrieved. The efficiencies of
TCM and control treatments were 87.18% and
65.63% , respectively. The results of heterogeneity
tests showed that the data were homogeneous
(P = 0.83), thus a fixed effects model was used for
analysis. The results revealed an odds ratio of 3.74
with a 95% confidence interval of 2.99-4.69. The
overall effectiveness value was 11.48 (P < 0.000 01).
These results suggest the efficacy of TCM therapy
for pSS better thanWestern Medicine.
CONCLUSION: Although our findings reveal that
the TCM treatment of pSS had significant advantag-
es over its counterpart, there were some flaws in
the studies included. The findings warrant further
investigation.
© 2016 JTCM. All rights reserved.
Key words: Primary Sjögren's syndrome; Clinical re-
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INTRODUCTION
Primary Sjögren's syndrome (pSS) is a chronic systemic
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autoimmune disease characterized by lymphocytic infil-
tration of the exocrine glands, especially the lacrimal
and salivary glands.1 Recent epidemiological studies re-
vealed that pSS was the second most common rheu-
matic disease in China with a prevalence of approxi-
mately 0.77% among the general population.2,3 The
use of Traditional Chinese Medicine (TCM) reportedly
has a positive effect for the treatment of pSS. More-
over, the use of TCM for treatment of pSS has advan-
tages over Western Medicine in terms of fewer side ef-
fects resulting in improved quality of life. Furthermore,
Chinese herbs used for the treatment of pSS are rela-
tively inexpensive. Therefore, the use of TCM conveys
many benefits to patients with pSS.Several review arti-
cles have evaluated the efficacy of TCM for the treat-
ment of pSS using systematic methods.4-7 However, a
significant drawback to these articles is that none made
a distinction between TCM and integrative medicine;
therefore, the effectiveness of TCM for the treatment
of pSS remains uncertain. It also remains unclear as to
whether TCM offers any advantages over the use of
Western Medicine. In this Meta-analysis, the efficacy
of TCM was compared to that of Western Medicine
for the treatment of pSS.
METHODS
Search strategy
We searched the following databases for studies on the
use of TCM and Western Medicine for the treatment
of pSS published in English or Chinese from January,
2000 to June, 2015: PubMed (http://www.ncbi.nlm.
nih.gov/pubmed), the Cochrane Library(www.co-
chranelibrary.com), the Web of Science (https://
isiknowledge.com), the China Knowledge Resource In-
tegrated Database (http://www.cnki.net/), the Chongq-
ing Vip Information Database (http://oldweb.cqvip.
com/), and the Wanfang Database (www.wanfangdata.
com.cn). Key words were used to search in PubMed.
The specific strategies were as follows: 1# 'Sjögren's
syndrome' AND 'Chinese medicine' AND 'random-
ized controlled trials'. 2# 'Sjögren's syndrome' AND
'Chinese medicine' AND 'clinical study'. 3# 'Sjögren's
syndrome' AND 'Chinese medicine' AND 'trial'.
Search strategy was slightly adjusted according to the
requirement of different databases. For the Chinese-lan-
guage search in CNKI, VIP, and WANFANG Data-
base, the search terms include 'Sjögren's syndrome' as
free text terms and then 'Chinese medicine' and 'ran-
domized controlled trials' as secondary retrieval. We al-
so reviewed the reference lists of all retrieved studies
and review articles.
Selection criteria
All randomized control trials (RCTs) were included re-
gardless of language. Studies that met the following cri-
teria were selected for further analysis: (a) Patients met
the diagnostic criteria for PSS and without having any
other serious diseases, (b) applied TCM therapy as the
only medications in the experiment group, (c) applied
Western Medicine therapeutic method alone in the
control group, (d) comprehensive evaluation of treat-
ment efficacy was examined by TCM, and also taking
into account other evaluation methods in Western
Medicine. The efficacy criteria referred to the Guiding
principle for clinical research on new drugs of Tradi-
tional Chinese Medicine issued by the China Ministry
of Health in 1995, or a tailored standard based on the
former criteria. The primary outcome was the total ef-
fective rate calculated by the following formula: the to-
tal effective rate = (number of significantly effective pa-
tients + number of effective patients)/total number of
patients × 100%. The patient was regarded as signifi-
cantly effective when TCM clinical symptoms, signs
and laboratory test improved significantly, and symp-
tom score reduced up to 70%. The patient was regard-
ed as effective when TCM clinical symptoms, signs
and laboratory test improved, and symptom score re-
duced up to 30%. The patient was regarded as invalid
when TCM clinical symptoms, signs and laboratory
test had no change or even deterioration, and symp-
tom score reduced less than 30%.
Data extraction and quality assessment
Important data extracted the following information
from each study: first author, year of publication, de-
mographic characteristics of the participants, total
number of included patients (cases and controls), blind
method, treatment, effective sample size, adverse reac-
tions and the outcomes of efficacy evaluation in trials
and controls. According to the predetermined selection
criteria, two reviewers (Liu Jingjing and Zhou Hong-
mei) independently screened the reports using a qualifi-
cation test. For any disagreements, a final decision was
made through discussions and consultations. The
study quality was evaluated as suggested in the Co-
chrane Handbook on the following areas: random se-
quence generation, allocation concealment, blinding of
participants and personnel, blinding of outcome assess-
ment, incomplete outcome data, and selective outcome
reporting were classified into low risk, high risk or un-
clear risk of bias for each item.8
Statistical analysis
Statistical analyses were performed with Review Manag-
er Software (version 5.0, the Nordic Cochrane Center,
the Cochrane Collaboration, Copenhagen, Denmark).
Dichotomous data are presented as the odds ratio (OR)
with 95% confidence intervals (CI). Continuous data
are presented as weighted means with 95% CI. A fixed-
or random-effect model was used according to hetero-
geneity.
RESULTS
Study selection and characteristics
The search results from different databases were inde-
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pendently entered into EndNote X7 reference manage-
ment software (endnote.com). Duplicated and clearly
non-relevant literature was excluded. The full texts of
relevant articles were downloaded or obtained by con-
tacting the authors. A total of 101 reports on the use of
TCM for treatment of pSS were retrieved from the lit-
erature. Of these, seven clinical studies conducted in
China were retrieved from the PubMed database,9-15
and one review paper was retrieved from the Web of
Science database,7 whereas all other papers were re-
trieved from Chinese databases. All of the research re-
ports were conducted in China. According to the afore-
mentioned screening criteria and double assessment by
two reviewers, 31 randomized controlled trials met the
inclusion criteria, which included 2135 cases (1139 cas-
es in the treatment group and 998 cases in the control
group).16-46 The literature screening process is illustrated
in Figure 1. The characteristics of the selected reports
are shown in Table 1.
Quality assessment
Among thirty one randomized controlled trials, twelve
were at low risk for bias for allocation sequence genera-
tion,18-20,24,26,33,34,38-41,43 while the remaining studies did not
report their randomization methods clearly. Only one
of the included studies reported the use of allocation
concealment and blinding.41 In addition, all studies
had low risk of bias in items of selective outcome re-
porting and incomplete outcome data. In summary, we
considered the overall risk of bias amongst our includ-
ed studies to be moderate (Figure 2).
All of the studies adopted comprehensive evaluation
criteria, in which 18 studies referred to the pSS evalua-
tion standard from the Guiding Principle of Clinical
Research on New Drugs of Traditional Chinese Medi-
cine issued by the China Ministry of Health in 1995,16,
18-20,22,25-28,32,34-37,40,41,43,46 another 13 studies used individual-
ly designed criteria according to the former,17,21,23,24,29-31,33,
38,39,42,44,45 and one study evaluated the treatment efficacy
using the Sjögren's Syndrome Disease Activity Index
(ESSDAI) as adopted by the European League Against
Rheumatism.39 In addition, the efficacy evaluation in-
dex also included symptomn (dry mouth and eyes, fa-
tigue, joint pain, etc.), eye examinations (tear flow rate,
corneal dyeing and Schirmer's test), inflammatory de-
tection (CRP and ESR), humoral immunity (immuno-
globulins), cell immunity (CD4 and CD8), autoanti-
body (SSA, SSB, Ro-52 and so on), salivary gland ex-
amination (salivary scintigraphy or flow rate) and labial
pathology. Among them, the most widely used is symp-
tom, inflammatory detection and humoral immunity
(Table 2).
Efficacy evaluation and side effects
Of the 1139 cases in the treatment group, outcomes of
993 cases were considered effective, indicating an effi-
ciency of up to 87.18%. Of the 998 cases in the con-
trol group, the outcomes of 655 cases were considered
effective, indicating an efficiency of 65.63% . We fur-
ther analyzed different control drugs and found that
the efficiency of different Western Medicines ranged
from 61.95% to 83.87%, while the efficiency of TCM
ranged from 77% to 92.33% (Table 3).
In all studies selected, drug safety was reported in 13
studies. Three articles reported adverse reactions in
treatment group, including stomach upset and diar-
rhea.29,32,39 These are all common side effects of Chinese
medicine. Seven articles reported adverse reactions in
control group, including abdominal pain, diarrhea,
blurred vision, central obesity, etc.24,26,28,29,34,35,39 In addi-
tion, five study reported no difference was found be-
tween two groups on drug safety.25,30,37,41,44
Meta-analysis
In 31 studies, cases were divided into two classifica-
Figure 1 Flowchart of literature search
CNKI: China National Knowledge Infrastructure Database; VIP: China Scientific Journals Database.
CNKI
(n = 33)
Wanfang
(n = 28)
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(n = 31)
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(n = 0)
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Duplicated (n = 52)
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tions. Outcomes classified as "significantly effective"
and "effective" were considered as effective, otherwise
they were considered as "no effect." Therefore, the over-
all clinical efficacy of TCM can be evaluated by Me-
ta-analysis. The heterogeneity test results indicated that
the data were not heterogeneous (χ2 = 22.58; P = 0.83
to > 0.1; I 2 = 0% to ≤ 50%), thus we employed a fixed
effect model for the Meta-analysis. Clinical efficacy test
results showed statistically significant differences be-
tween the TCM treatment group and Western Medi-
cine control group (OR = 3.74; 95% CI = 2.99-4.69;
Z = 11.48; P < 0.000 01) (Figure 3). In order to deter-
mine the effect size, OR and OR standard error were de-
fined as the X- and Y-axis, respectively. Review Manag-
er 5.0 software was used to construct funnel plots of
the data included in the 31 studies (Figure 4).
DISCUSSION
Meta-analysis is a systematic, quantitative comprehen-
sive approach for the analysis of a number of indepen-
dent studies on the same issue. In a quantitative litera-
ture review, multiple studies on the same research ques-
tion are treated as a multi-center study, thus multi-cen-
ter statistical methods are used to conduct comprehen-
sive analyses.47,48 Meta-analysis is widely used in clinical
and epidemiological studies to evaluate the diagnosis,
treatment outcomes, efficacy of therapeutic agents, risk
assessment, intervention methods, and prevention mea-
sures to provide reliable scientific evidence for clinical
practice.49-51
Efficacy of TCM for treatment of pSS
The retrieved clinical trials reported statistically signifi-
cant differences for the efficacy of TCM vs Western
Medicine. According to the forest plot presented in Fig-
ure 3, the 95% CI of the combined effect size of the
OR lies to the right of the vertical, which is the side of
the TCM treatment group, indicating that the efficacy
of TCM was superior to that of Western Medicine for
the treatment of pSS. Only one study reported that the
efficacy of TCM treatment was poorer than that of
Western Medicine37. The total efficiencies of TCM and
Western Medicine were 87.18% and 65.63% , respec-
tively. From the inverted funnel plot in Figure 4, we
found that the inclusion studies were on both sides of
the dotted line and the plot was skewed, which sug-
gests the presence of publication bias. Overall, the in-
cluded studies reported only the advantages and effec-
tiveness of TCM. However, the researchers may have
paid more attention to the positive results and less on
any negative results.
Problems with clinical research
Due to the limited number of clinical trials of TCM
for treatment of pSS, we included total glucosides of
peony and Tripterygium wilfordii glycosides in the con-
trol group, as these drugs are usually clinically used as
immunosuppressant or immunomodulatory agents. In
addition, clinical studies of TCM for the treatment of
pSS have many deficiencies. First, there are no strict di-
agnostic criteria. At present, a diagnosis of pSS is based
on the 2002 international classification criteria. Howev-
er, six of the included 31 papers adopted other diagnos-
tic criteria.21-23,30,42,44 Histological and autoantibody anal-
yses are particularly emphasized in the diagnostic crite-
ria, although only one of the two is necessary to arrive
at a diagnosis. Since primary hospitals often did not
conduct relevant tests, there was a deviation in the
number of selected cases.52 Second, the experimental
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design of these studies was unreasonable. Of the 31
studies, twelve mentioned a random number grouping
method,18-20,24,26,33,34,38-41,43 one adopted single-blind ran-
domized study,41 no study employed a double-blind pla-
cebo experimental method, subject age was not report-
ed in eight studies,16,18,19,23,28,33,38,42 and drug safety was
evaluated only in 14 studies. Finally, the evaluation
methods used in these studies were relatively uniform.
Regarding the comprehensive evaluation of the efficacy
of TCM, 13 studies adopted self-designed efficacy stan-
dards, while only one study used the Short Form (36)
Health Survey,40 Sheehan Disability Scale,40 and ESS-
DAI to assess efficacy.39 Hence, studies of TCM should
adopt international evaluation standards to promote in-
ternational studies of the efficacy of TCM and reduce
bias arising from efficacy evaluation. In addition, the
use of TCM was reported to improve clinical symp-
toms of pSS, such as dry mouth, dry eyes, etc. Howev-
er, clinical symptoms were not observed or reported in
13 studies. Meanwhile, red coloration and scanty coat-
ing of the tongue are common symptoms of pSS, and
also reflect treatment efficacy.54 Unfortunately, these
tongue symptoms were addressed in only three stud-
ies.20,43,45 Moreover, 22 studies adopted erythrocyte sedi-
mentation rate and C-reactive protein levels, 17 studies
observed immunoglobulin changes, one study reported
labial pathology,22 five studies adopted autoantibody in-
dicators,21,29,35,38,41 and no study employed saliva scintig-
raphy. In short, current evaluation standards are insuffi-
cient for applications to international research.
Prospects for future clinical research of pSS
A good research design is necessary to arrive at reliable
conclusions. Future clinical research on the efficacy of
TCM for the treatment of pSS should adhere to uni-
fied diagnostic criteria, according to the evidence based
medicine principle, and employ a randomized con-
trolled experimental design. For evaluation, we should
try to choose key indicators reflecting efficacy, such as
the ESSDAI, dry mouth, dry eyes, Schirmer's test, sali-
vary flow rate, corneal staining, erythrocyte sedimenta-
tion rate, C-reactive protein levels, autoantibody con-
centrations, etc. Furthermore, future studies should
consider indicators of TCM characteristics, such as
symptoms of the tongue and fatigue. Eventually, TCM
preparations should be regulated to avoid the use of dif-
ferent compounds or doses. On the whole, comparabil-
ity between different studies can be increased by im-
proving the research design.55
In conclusion, in this review, we compared the thera-
peutic effect of TCM and Western Medicine for the
treatment of pSS. Overall, the evidence suggests that
the efficacy of TCM for the treatment of pSS was bet-
ter than that of Western Medicine. Some flaws were
found in most of TCM clinical studies included, such
as no strict diagnostic criteria, unreasonable experimen-
tal designs, non-uniform evaluation methods, etc.
Therefore, the findings require further confirmation.Tab
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